Cancer News and Research

Latest Cancer News and Research

Beta blockers improve heart function; eliminate need for implantable cardiac devices

New Saint Louis University research has found that beta blockers, a class of drugs used to prevent the progression of heart failure and manage arrhythmias (irregular heart beat) and hypertension (high blood pressure), are underused in heart failure patients who receive implantable cardiac devices.

4 Mar 2010

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the FDA for ZoraxelTM for the treatment of erectile dysfunction (ED).

4 Mar 2010

Prolonged use of HRT may increase risk of lung cancer

Women aged 50 to 76 who take estrogen plus progestin may have an increased risk of lung cancer, according to a new study published in the pre-print online edition of the Journal of Clinical Oncology.

4 Mar 2010

Covidien: Mallinckrodt launches Oral Transmucosal Fentanyl Citrate

Covidien, a leading global provider of healthcare products, today announced that Mallinckrodt Inc., a Covidien company, has launched its Oral Transmucosal Fentanyl Citrate (CII) to distributors serving retail pharmacies across the country.

3 Mar 2010

$Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer$

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.

3 Mar 2010

CRH Medical receives Japanese Notice of Allowance for CRH O'Regan System

CRH Medical Corporation announced today that the Japanese Patent Office has provided a Notice of Allowance for a patent application filed by the Company and related to CRH Medical's hemorrhoid technology, the CRH O'Regan System(TM). The Japanese patent is expected to be issued in the next several weeks and will provide additional protection to the Company's proprietary technology platform.

3 Mar 2010

AUA Foundation joins AUA in response to the ACS updated prostate cancer screening guidelines

The American Urological Association Foundation joins the AUA in its response to the American Cancer Society updated prostate cancer screening guidelines highlighting the importance of shared decision-making between patients and physicians.

3 Mar 2010

Shock: Norepinephrine favored over dopamine

Physicians treating patients with shock should consider norepinephrine instead of dopamine as a tool for stabilizing blood pressure, according to an editorial in the March 4, 2010, issue of the New England Journal of Medicine (NEJM).

3 Mar 2010

Gene 'addiction' of leukaemia cells

An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.

3 Mar 2010

Shortage of donated blood in the U.S.: Research looks for ways to improve life-saving supply

There is typically a shortage of donated blood in the United States, and research at Case Western Reserve University is looking for ways of improving the life-saving supply.

3 Mar 2010

Seattle Genetics generates $110M through ADC technology license agreements

Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Genentech, Inc., a wholly owned member of the Roche Group.

3 Mar 2010

UPMC develops its first EHR application for BlackBerry smartphones

In an effort to put critical patient information in the hands of physicians at the bedside, UPMC announced today that it has developed its first electronic health record (EHR) application for BlackBerry® smartphones. The pilot project gives physicians access to such information as a patient’s allergies, current medications and recently completed lab tests.

3 Mar 2010

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.

3 Mar 2010

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week’s DNA Vaccines 2010 in New Orleans, LA concerning the formulation and topical administration of the DermaVir therapeutic vaccine for HIV/AIDS. DNA Vaccine 2010 invites leading scientists to report on the latest research in the progressive field of DNA or Genetic Vaccines.

3 Mar 2010

New QUANTEC guidelines for safe treatment of cancer with radiation therapy

The culmination of a two-year effort to review available studies and establish new guidelines for the safe treatment of cancer with radiation therapy was published today in the International Journal of Radiation Oncology, Biology and Physics.

3 Mar 2010

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck & Co., Inc. today announced its updated, newly integrated, late-stage pipeline following its recent merger with Schering-Plough. The new pipeline features a broad and diversified portfolio of investigational medicines and vaccines, including more than 20 candidates in Phase III or under regulatory review, and more than 20 candidates in Phase II of development.

3 Mar 2010

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.

3 Mar 2010

Toxins in K2: Saint Louis University professor warns parents to lookout for warning signs

In the last month, Anthony Scalzo, M.D., professor of toxicology at Saint Louis University, has seen nearly 30 cases involving teenagers who were experiencing hallucinations, severe agitation, elevated heart rate and blood pressure, vomiting and, in some cases, tremors and seizures. All of these teens had smoked a dangerous, yet legal substance known as K2 or "fake weed."

3 Mar 2010

SCLL signs agreement to provide research and assay services in support of Agennix's talactoferrin program

Stem Cell Innovations announced today that the Company has signed a Master Services Agreement to provide research and assay services in support of Agennix's talactoferrin program. The assay utilizes SCLL's C3A human liver cell line.

3 Mar 2010

Enanta Pharmaceuticals nominates EDP-239 lead development candidate from NS5A HCV inhibitor program

Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing.

3 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Beta blockers improve heart function; eliminate need for implantable cardiac devices

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

Prolonged use of HRT may increase risk of lung cancer

Covidien: Mallinckrodt launches Oral Transmucosal Fentanyl Citrate

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

CRH Medical receives Japanese Notice of Allowance for CRH O'Regan System

AUA Foundation joins AUA in response to the ACS updated prostate cancer screening guidelines

Shock: Norepinephrine favored over dopamine

Gene 'addiction' of leukaemia cells

Shortage of donated blood in the U.S.: Research looks for ways to improve life-saving supply

Seattle Genetics generates $110M through ADC technology license agreements

UPMC develops its first EHR application for BlackBerry smartphones

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

New QUANTEC guidelines for safe treatment of cancer with radiation therapy

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

Toxins in K2: Saint Louis University professor warns parents to lookout for warning signs

SCLL signs agreement to provide research and assay services in support of Agennix's talactoferrin program

Enanta Pharmaceuticals nominates EDP-239 lead development candidate from NS5A HCV inhibitor program

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in